Home＞REGULATORY
3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing(May.17.2017)
FPMAJ Chairman Masayo Tada (left), JPMA President Yoshihiko Hatanaka |
Three major pharma trade groups of Japan, the US, and Europe all pressed for a scheme to keep NHI drug prices for the duration of the patent term at a hearing of a key drug pricing panel on May 17 - aiming to turn the tide amid a growing headwind for the so-called price maintenance premium ...
(LOG IN FOR FULL STORY)
-
Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May.19
-
JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May.19
-
JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May.19
-
FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May.18
-
(Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May.18
-
Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May.17
-
Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May.17
-
- Conditional Early Approval System Gets Underway: MHLW Oct.23
-
LDP Healthcare Big Names Handily Nab Seats in Snap Election
Oct.23
- MHLW to Discuss Drug Wholesalers’ License Requirements Related to Their “Operational Systems” Oct.23
-
MHLW to Discuss Redefinition of Drug “Seals”, Will Revise List of Examples of Seals Included in 1961 Notification
Oct.23
-
Japan Introduction of GDP Likely to Begin with Guideline that Calls on Companies to Make “Good Faith Effort”: MHLW Study Group
Oct.23
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed(Oct.24)
- Shionogi Ups Earnings Outlook on Milestone Scheme Change(Oct.24)
- AZ’s Olaparib Filed for Breast Cancer in 2nd Submission(Oct.24)
- Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030(Oct.24)
- Conditional Early Approval System Gets Underway: MHLW(Oct.23)
